Khartis Therapeutics key facts
- Developer of oral therapies designed for patients with immune-mediated and chronic diseases.
- Khartis Therapeutics’s last known valuation is $74.0M.
- It has raised $44.5M; the latest was Early Stage VC ($40.0M) in Nov 2024.
- Notable investors include Foresite Capital, Lilly Asia Ventures, Nextech Invest.
- Status: Privately Held (backing).
Who backs Khartis Therapeutics
3- ·Watch Khartis Therapeutics: the Monday email on marks, rounds and moves
Khartis Therapeutics funding rounds
No funding rounds for Khartis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Khartis Therapeutics valuation
Khartis Therapeutics's last known valuation is $74 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Khartis Therapeutics investors
3 investors are on record for Khartis Therapeutics, including Foresite Capital, Lilly Asia Ventures and Nextech Invest.
About Khartis Therapeutics
Developer of oral therapies designed for patients with immune-mediated and chronic diseases. The company's drug discovery team focuses on creating impactful small molecule treatments through scientific innovation and translational research, enabling the advancement of meaningful therapies that address significant unmet medical needs.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Website
- khartis.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Khartis Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.